Andere Sprachen Merck & Co., Inc.

Aktien

A0YD8Q

US58933Y1055

MRK

Pharmazeutika

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:50:10 09.12.2024			% 5 Tage	% 1. Jan.
103,84 ^USD	+0,73 %		+3,19 %	-4,77 %

13:29	Keytruda von Merck in Kombination mit Chemotherapie und Lynparza-Regime erreicht primären Endpunkt der Phase 3	MT
11:03	Studie von Merck zeigt vollständige Ansprechrate von 100% für Zilovertamab Vedotin mit R-CHP bei Krebspatienten	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Merck's Keytruda Combined With Chemotherapy and Lynparza Regimen Meets Phase 3 Primary Endpoint	13:29
Merck : résultats encourageants dans le lymphome diffus	13:04
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer	12:46
Merck's Study Shows Complete Response Rate of 100% for Zilovertamab Vedotin With R-CHP in Cancer Patients	11:03
Merck & Co., Inc. Announces First Presentation of Data from the Phase 2 Waveline-007 Trial Evaluating Zilovertamab Vedotin	08.12.
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma	08.12.
Merck : Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025	05.12.
Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025	05.12.
Merck : démarrage d'un essai de phase III dans le Covid-19	05.12.
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults	05.12.
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults	05.12.
Merck & Co., Inc. Announces Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOTM (Molnupiravir) for the Treatment of Covid-19 in High-Risk Adults	05.12.
From Fed foresight to French fears	04.12.
Analyst recommendations: Merck, Salesforce, Block, Lyft, Bunzl...	04.12.
Cyber Insurance Update: Recent Decisions Addressing Coverage For Cyber Losses	04.12.
Merck : 'percée thérapeutique' pour un anticorps-conjugué	03.12.
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation	03.12.
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations	03.12.
Merck's Sacituzumab Tirumotecan Granted FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC	03.12.
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	29.11.
Dr. Reddy's Laboratories Launches Anti-Parasitic Drug Ivermectin	26.11.
Merck to Participate in the Citi 2024 Global Healthcare Conference	26.11.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Data	25.11.
Merck : succès d'une étude dans l'hypertension artérielle	25.11.
Merck Heart Disease Drug Meets Target in Phase 3 Study	25.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Merck & Co., Inc.

Aktien

A0YD8Q

US58933Y1055

MRK

Pharmazeutika

Andere Sprachen

Filter